market access Archives - Page 6 of 50 -

When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides

Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation

https://pharmaphorum.com/views-and-analysis/global-impact-how-regulatory-affairs-is-shaping-development-of-cutting-edge-pharma-innovation/

Market Access/ News/ News

EU stops short of vaccine export controls after summit

Richard Staines AstraZeneca, market access, vaccine 0 Comment

The European Union has stopped short of export controls on vaccines after leaders met at a summit to

EU stops short of vaccine export controls after summit

https://pharmaphorum.com/news/eu-stops-short-of-vaccine-export-controls-after-summit/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Market Access/ News/ News

NICE backs ovarian cancer and multiple myeloma combination drugs

Richard Staines market access, multiple myeloma, NICE, ovarian cancer 0 Comment

NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft

NICE backs ovarian cancer and multiple myeloma combination drugs

https://pharmaphorum.com/news/nice-backs-ovarian-cancer-and-multiple-myeloma-combination-drugs/

Market Access/ News/ News

NICE axes funding for MSD’s Keytruda in bladder cancer despite appeal

Richard Staines bladder cancer, cancer, Keytruda, market access, NICE 0 Comment

NICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal

NICE axes funding for MSD’s Keytruda in bladder cancer despite appeal

https://pharmaphorum.com/news/nice-axes-funding-for-msds-keytruda-in-bladder-cancer-despite-appeal/

Market Access/ News/ News

Novartis says £1.8m Zolgensma is model for gene therapy pricing

Richard Staines market access, Novartis, spinal muscular atrophy, Zolgensma 0 Comment

Novartis has said its gene therapy pricing model, involving a steep one-off payment, could be a template for

Novartis says £1.8m Zolgensma is model for gene therapy pricing

https://pharmaphorum.com/news/novartis-e1-9m-zolgensma-is/

Market Access/ News/ News

NICE says NHS should fund Novartis’ £1.79m SMA gene therapy

Richard Staines market access, NICE, Novartis, SMA 0 Comment

The NHS should pay for Novartis’ £1.79 million one-off gene therapy for Spinal Muscular Atrophy (SMA) NICE has

NICE says NHS should fund Novartis’ £1.79m SMA gene therapy

https://pharmaphorum.com/news/nice-says-nhs-should-fund-novartis-1-79m-sma-gene-therapy/

Market Access/ News/ News

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

Richard Staines breast cancer, cancer, Cancer Drugs Fund, Kisqali, market access, NICE 0 Comment

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

https://pharmaphorum.com/news/nice-okays-regular-nhs-funding-for-novartis-breast-cancer-drug-kisqali/

Market Access/ News/ News

AZ to divert COVID-19 vaccines from global supply chain to meet EU target

Richard Staines AstraZeneca, COVID-19, market access, vaccine 0 Comment

AstraZeneca has said it will be able to meet a target to deliver 180 million COVID-19 vaccines to

AZ to divert COVID-19 vaccines from global supply chain to meet EU target

https://pharmaphorum.com/news/az-to-miss-q2-covid-19-vaccine/

Market Access/ News/ News

Europe orders another 200m doses of Pfizer/BioNTech COVID shot

Richard Staines AstraZeneca, BioNTech, market access, Pfizer, vaccine 0 Comment

The European Commission has ordered another 200 million doses of the Pfizer/BioNTech COVID-19 vaccine Comirnaty, bringing the bloc’s

Europe orders another 200m doses of Pfizer/BioNTech COVID shot

https://pharmaphorum.com/news/europe-orders-another-200m-doses-of-pfizer-biontech-covid-shot/

Trending

market access

Login